Quantbot Technologies LP Purchases 15,416 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Quantbot Technologies LP boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 489.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 18,566 shares of the specialty pharmaceutical company’s stock after buying an additional 15,416 shares during the period. Quantbot Technologies LP’s holdings in Supernus Pharmaceuticals were worth $585,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC raised its stake in shares of Supernus Pharmaceuticals by 92.4% in the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock valued at $97,000 after acquiring an additional 1,479 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Supernus Pharmaceuticals by 8.8% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock valued at $453,000 after purchasing an additional 1,161 shares in the last quarter. Meritage Portfolio Management raised its position in Supernus Pharmaceuticals by 2.7% in the 2nd quarter. Meritage Portfolio Management now owns 60,398 shares of the specialty pharmaceutical company’s stock valued at $1,904,000 after purchasing an additional 1,595 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Supernus Pharmaceuticals by 50.2% in the second quarter. Envestnet Asset Management Inc. now owns 90,525 shares of the specialty pharmaceutical company’s stock worth $2,853,000 after purchasing an additional 30,256 shares in the last quarter. Finally, QRG Capital Management Inc. grew its holdings in shares of Supernus Pharmaceuticals by 7.4% during the second quarter. QRG Capital Management Inc. now owns 18,892 shares of the specialty pharmaceutical company’s stock worth $595,000 after purchasing an additional 1,309 shares during the last quarter.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $46.16 on Thursday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The firm has a market capitalization of $2.65 billion, a P/E ratio of -135.76, a P/E/G ratio of 0.55 and a beta of 0.71. The company’s 50 day simple moving average is $48.28 and its 200 day simple moving average is $41.64.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The business had revenue of $170.00 million for the quarter, compared to analyst estimates of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.Supernus Pharmaceuticals’s revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.69 EPS. Sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. TD Cowen lifted their price target on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Piper Sandler raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. Bank of America initiated coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price objective for the company. Finally, Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a report on Tuesday, September 30th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $63.25.

Insider Transactions at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 59,900 shares of the company’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the completion of the sale, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at $61,016,649.46. This represents a 4.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $45.87, for a total transaction of $229,350.00. Following the transaction, the senior vice president directly owned 15,496 shares in the company, valued at $710,801.52. The trade was a 24.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 121,235 shares of company stock valued at $5,923,797 in the last quarter. 8.80% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.